Alzheimer's disease (AD) is a progressive dementia caused by degeneration of the central nervous system with a high incidence in the elderly. Resveratrol is a natural compound contained in a wide range of plant species, including grapes. Recent studies have shown positive effects of resveratrol in animal models of AD; however, whether these results justify clinical trials is uncertain. Furthermore, there are multiple theories about the mechanism(s) by which resveratrol works and knowing how it works can suggest targets for future drug development. So far, systematic evaluation of both of these aspects is lacking. In this study, we selected 19 studies describing the efficacy of resveratrol in rodent AD models by electronic and manual retrieval. The method quality of the study were analyzed by the SYRCLE's risk of bias tool and the experimental data were retrieved and meta-analyzed using forest plot. Analysis of these studies demonstrates the consistent neuroprotective effects of resveratrol in AD models and offers insights into the possible pharmacological mechanisms. This information eliminates the bias of each study, providing supporting evidence for the implementation of clinical trials. However, the limits of studies were also noticed: low method quality, lack of sample size calculation and high risks of bias.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.phrs.2019.104476 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GraphkmerDTA: integrating local sequence patterns and topological information for drug-target binding affinity prediction and applications in multi-target anti-Alzheimer's drug discovery.
Mol Divers
January 2025
Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases Ministry of Education, Jiangxi Province Key Laboratory of Biomaterials and Biofabrication for Tissue Engineering, Gannan Medical University, Ganzhou, 341000, Jiangxi, China.
Identifying drug-target binding affinity (DTA) plays a critical role in early-stage drug discovery. Despite the availability of various existing methods, there are still two limitations. Firstly, sequence-based methods often extract features from fixed length protein sequences, requiring truncation or padding, which can result in information loss or the introduction of unwanted noise.
View Article and Find Full Text PDFCalcium Signalling in Neurological Disorders, with Insights from Miniature Fluorescence Microscopy.
Cells
December 2024
Neural Dynamics Laboratory, Department of Medicine, The University of Melbourne, Melbourne, VIC 3052, Australia.
Neurological disorders (NDs), such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and schizophrenia, represent a complex and multifaceted health challenge that affects millions of people around the world. Growing evidence suggests that disrupted neuronal calcium signalling contributes to the pathophysiology of NDs. Additionally, calcium functions as a ubiquitous second messenger involved in diverse cellular processes, from synaptic activity to intercellular communication, making it a potential therapeutic target.
View Article and Find Full Text PDFThe Beneficial Effects of Lactobacillus Strains on Gut Microbiome in Alzheimer's Disease: A Systematic Review.
Healthcare (Basel)
January 2025
Neuroimmunology Laboratory, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Background/objectives: Growing evidence suggests that the gut-brain axis influences brain function, particularly the role of intestinal microbiota in modulating cognitive processes. Probiotics may alter brain function and behavior by modulating gut microbiota, with implications for neurodegenerative diseases like Alzheimer's disease (AD). The purpose of this review is to systematically review the current literature exploring the effects of probiotic supplementation on gut microbiota and cognitive function in AD and mild cognitive impairment (MCI).
View Article and Find Full Text PDFNeuropsychological test performance in mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis.
Alzheimers Dement
January 2025
Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Stockholm, Sweden.
Background: We sought to characterize the cognitive profile among individuals with mild cognitive impairment with Lewy bodies (MCI-LB) to help guide future clinical criteria.
Methods: Systematic review and meta-analysis included MCI-LB studies with cognitive data from PubMed, Embase, Web of Science, and PsycINFO (January 1990 to March 2023). MCI-LB scores were compared to controls, MCI due to Alzheimer's disease (MCI-AD), and dementia with Lewy bodies (DLB) groups with random-effects models.
Bibliometric Study of Periodontitis and Alzheimer's Disease: Trends, Collaboration, and Emerging Patterns.
J Contemp Dent Pract
September 2024
Bibliometrics, Evidence Evaluation and Systematic Reviews (BEERS) Group, Human Medicine Career, Universidad Científica del Sur, Lima, Peru, Phone: +5113171023, e-mail:
Aim: To perform a bibliometric study of periodontal disease and Alzheimer's disease (AD) focusing on trends, collaborative efforts, and emerging patterns.
Materials And Methods: From January 2018 to May 2024, an observational study was carried out utilizing metadata extracted from the Scopus database. A search methodology, specifically designed for this database, was developed using MeSH terms combined with Boolean operators such as "AND" and "OR".
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!